title: The pathophysiology and pharmacology of hepcidin.
abstract: Inappropriate production of the iron-regulatory hormone hepcidin contributes to the pathogenesis of common iron disorders. Absolute or relative deficiency of hepcidin causes iron overload in hereditary hemochromatosis and iron-loading anemias. Elevated hepcidin causes iron restriction in inflammatory conditions including autoimmune disease, critical illness, some cancers, and chronic kidney disease. Multiple agents targeting hepcidin and its regulators are under development as novel therapeutics for iron disorders. This review summarizes hepcidin biology and discusses the current landscape for hepcidin-targeting therapeutic strategies.
authors.affiliation: Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
authors.forename: Piotr
authors.initials: P
authors.lastname: Ruchala
authors.affiliation: Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: enemeth@mednet.ucla.edu.
authors.forename: Elizabeta
authors.initials: E
authors.lastname: Nemeth
mesh_terms: D000740:Anemia / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D064451:Hepcidins / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism
chemical_list: D064451:Hepcidins; D007501:Iron
keywords: anemia; ferroportin; iron disorders; iron overload